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Aim: The study aim was to evaluate whether circulating microparticles with apoptotic or non-apoptotic
phenotypes are useful for risk assessment of 3-year cumulative fatal and non-fatal cardiovascular events in
CHF patients.
Methods: The incidence of fatal andnon-fatal cardiovascular events, aswell as the frequency of occurrence of death
from any cause in a cohort of 388 patients with CHF during 3 years of observation was studied prospectively. Cir-
culating levels of NT-pro brain natriuretic peptide (NT-pro-BNP), high-sensitivity C-reactive protein (hs-CRP), and
endothelial apoptotic microparticles (EMPs) were measured at baseline.
Results:Median follow-upwas 2.32 years (IQR=1.8–3.1). During follow-up, 110 cardiovascular events (including
43 fatal cases) were determined. Additionally, 74 subjects were hospitalized repetitively due to worsening CHF
and also 16 subjects were readmitted in the hospital due to other cardiovascular reasons. In the univariate logistic
regression analysis, the main factors independently related with cumulative endpoints were creatinine, fasting
glucose, HbA1c, total cholesterol, uric acid, various types of EPMs, NT-pro-BNP, hs-CRP, NYHA class, decreased
left ventricular ejection fraction (LVEF) less 45%, and type 2 diabetes mellitus. In multivariate model NYHA
class, decreased LVEF (less 45%), NT-pro-BNP, hs-CRP, CD144+/CD31+/annexin V+ EMPs, and CD31+/annexin
V+ EMPs remained statistically signiﬁcant for cumulative endpoint. Adding of CD144+/CD31+/annexin V+
EMCs and CD31+/annexinV+EMCs to the standard ABCmodelmay improve the relative IDI for cumulative end-
point by 11.4% and 10.5% respectively.
Conclusion: Apoptotic phenotype of circulating microparticles may relate 3-year combined clinical outcomes in
CHF patients.© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Chronic heart failure (CHF) remains a leading cause of cardiovascu-
lar morbidity and mortality [1]. Moreover, the frequencies of novel
cases of CHF arise progressively worldwide [2]. Although the endotheli-
um is considered an important target for traditional risk factors and
endothelial dysfunction remained independently associated with
mortality from CHF [3,4], the innate molecular mechanisms affected
forming endothelial dysfunction are not fully clear. In this context, sys-
temic pro-inﬂammatory activation, metabolic comorbidities, andding agency in the public, com-
. This is an open access article underneurohumoral state are considered the origin of microvascular endo-
thelial cell inﬂammation that leads to the development of CHF and sup-
ports cardiac remodeling and vascular dysfunction [4]. Moreover,
endothelial dysfunction is suggested as an early event in the develop-
ment and progression of CHF. However, biological markers of endothe-
lial dysfunction are abundant; there remains no ideal indicators that
relate to the several faces of the pathogenesis of CHF [5,6]. The
European Society of Cardiology and the American Heart Association/
American Colleges of Cardiology have recently published a set of current
biomarkers with high predictive value and powerful diagnostic capacity
for subjectswith CHF,which include natriuretic peptides, cardiac specif-
ic troponin, galectin-3, and high-sensitivity C-reactive protein [7–9].
Although all these markers have obvious advantages and some disad-
vantages too, there are several limitations regarding interpretations
and implementation of obtained ﬁndings in risk stratiﬁcation among
CHF patients [10]. Collectively, discovering new biomarkers that closelythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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stages of disease appears to be attractive. Taking into consideration
the pathogenesis of CHF and the role of endothelial dysfunction in na-
ture evolution of cardiac failure, small-size cell membrane vesicles,
such asmicroparticles, that are derived from activated cells or apoptotic
particles, might be useful for risk stratiﬁcation of the subjects with CHF.
Indeed, wide spectrum endothelial cell‐, platelet‐, and monocyte/mac-
rophage‐derivedmicroparticles have recently been associatedwith car-
diovascular and metabolic diseases, inﬂammatory state, and
autoimmune conditions.
Endothelial-derived microparticles (EMPs) are a novel biological
marker of endothelial injury and vascular tone disorders [11,12]. EMPs
are deﬁned as a heterogeneous population of vesicles (diameter of
100–1000 nm) that are released by cellular vesiculation and ﬁssion of
the membrane of endothelial cells [13]. EMPs derive from activated or
apoptotic endothelial cells andmay play a pivotal role in the vascular re-
modeling and endothelial reparation [14,15]. Biological effect of EMPs
may mediate by supporting cell-to-cell cross-talking because EMPs
transport miRNA, active molecules, hormones, peptides, regulator pro-
teins, etc. [16,17]. Probably, EMPs may contribute to hyperadrenergic
state in CHF via regulation of adrenal signaling [18,19]. However,
knowledge on EMPs is sufﬁciently limited due to their sub-
micrometer size and to intrinsic limitations in methods applied for
their determination,while their role in CHF is probably underestimated.
The study aim was to evaluate whether circulating endothelial-derived
microparticles with apoptotic or non-apoptotic phenotypes are useful
for risk assessment of 3-year cumulative fatal and non-fatal cardiovas-
cular events in CHF patients.2. Methods
2.1. Study population
The study population consisted of 388 consecutive patientswith CHF
who underwent angiography or PCI between April 2010 and June 2014,
aswell as referred as post-myocardial infarction subjectswithin this pe-
riod in the ﬁve centers which participated in this investigation. All these
patients were selected from 1427 patients according to our inclusion
and exclusion criteria. The study protocol was approved by the
Zaporozhye State Medical University ethics committee review board.
The study complied with the Declaration of Helsinki and voluntary in-
formed written consent was obtained from all patients included in
this study.
Prognosis was assessed by the composite endpoint related to
all-cause death, CHF-related death or CHF hospitalization, censored at
3 years.2.2. Methods for visualization of coronary arteries
Multispiral computed tomography angiography and/or angiograph-
ic study have been carried out to verify the ischemic nature of the dis-
ease in patients. Multispiral computed tomography angiography has
been carried out for all the patients prior to their inclusion in the
study. When atherosclerotic lesions of the coronary arteries were veri-
ﬁed, patients were subjected to conventional angiographic examination
provided indications for revascularization were available. CAD was
considered to be diagnosed upon availability of previous angiographic
examinations carried out not later than 6 months ago provided no
new cardiovascular events occurred for this period, and the procedure
is available for assay. The coronary artery wall structure was measured
by contrast-enhanced spiral computed tomography angiography [20]
on Somatom Volume Zoom scanner (Siemens, Erlangen, Germany)
with two detector rows using non-ionic contrast Omnipaque
(Amersham Health, Ireland).2.3. Echocardiography and tissue Doppler imaging
Transthoracic B-mode echocardiography and tissue Doppler imag-
ing were performed according to a conventional procedure on
ACUSON scanner (SIEMENS, Germany) using phased transducer of
5 МHz. Left ventricular end-diastolic and end-systolic volumes, and
ejection fraction (LVEF) were measured by modiﬁed Simpson's plani-
metric method [21,22]. Inter- and intra-observer variability coefﬁcients
for LVEF were 3.2% and 1.1% respectively.
2.4. Glomerular ﬁltration rate measurement
Calculation of glomerular ﬁltration rate (GFR) was calculated by
CKD-EPI formula [23].
2.5. Biomarker determination
All biomarkers were determined at baseline. To measurement of
biological marker concentrations, blood samples were drawn in the
morning (at 7–8 a.m.) into cooled silicone test tubes. Samples were
processed according to the recommendations of the manufacturer of
the analytical technique used. They were centrifuged upon permanent
cooling at 6000 rpm for 3 min. Then, plasma was refrigerated immedi-
ately to be stored at a temperature−70 °С until measurement.
Circulating NT-pro-BNP level was measured by immunoelectro-
chemoluminescent assay using sets produced by R&D Systems (USA)
on Elecsys 1010 analyzer (Roche, Mannheim, Germany). The high-
sensitivity C-reactive protein (hs-CRP) levels were measured by using
nephelometric technique on AU640 analyzermanufactured byDiagnostic
Systems Group (Japan).
Concentrations of total cholesterol (TC) and cholesterol of high-
density lipoproteins (HDLP) were measured by the fermentationmeth-
od. Concentration of cholesterol of low-density lipoproteins (LDL-C)
was calculated according to the Friedewald formula (1972).
A total of 100 μL of serum samples was assayed in parallel to known
standard concentrations for each biological marker. The mean intra-
assay coefﬁcients of variation were b10% of all cases.
2.6. Endothelial-derived apoptotic and activatedmicroparticle determination
Endothelial-derived apoptotic and activated microparticles were
phenotyped byﬂow cytometry by phycoerythrin (PE)-conjugatedmono-
clonal antibody against CD31 (platelet endothelial cell adhesionmolecule
[PECAM]-1), CD144 (vascular endothelial [VE]-cadherin), CD62E (E-
selectin), and annexin V (BD Biosciences, USA) followed by incubation
with ﬂuorescein isothiocyanate (FITC)-conjugated annexin V (BD Biosci-
ences, USA) per HD-FACS (High-Deﬁnition Fluorescence Activated Cell
Sorter) methodology. The samples were incubated in the dark for
15 min at room temperature according to the manufacturer's instruc-
tions. The samples were then analyzed on a FC500 ﬂow cytometer
(Beckman Coulter). For determination of annexin V+ EMPs 400 μL
annexin V binding buffer was added. For each sample, 500,000 events
have been analyzed. EMPs gate was deﬁned by size, using 0.8 and
1.1 mm beads (Sigma, St. Louis, MO, USA). CD31+/annexin V+ and
CD144+/CD31+/annexin V+microparticles were deﬁned as apoptotic
EMPs, EMPs positively labeled for CD62E+ were determined as EMPs
produced due to activation of endothelial cells. Therefore, double-
positive EMPs (CD31 and CD144) and triple-positive (CD144+/
CD31+/annexin V+) were deﬁned as most speciﬁc EMPs [24,25].
2.7. Statistical analysis
Statistical analysis of the results obtained was carried out in SPSS
system for Windows, Version 22 (SPSS Inc., Chicago, IL, USA) and
GraphPad Prism for Windows, Version 5 (GraphPad Software Inc., La
Jolla, CA, USA). The data were presented as mean (М) and standard
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terquartile range (IQR), as well as number (n) and frequencies (%) for
categorical variables. To compare the main parameters of patients'
groups (subject to the type of distribution of the parameters analyzed),
two-tailed Student's t-test or Mann–Whitney U-test was used. To com-
pare categorical variables between groups, chi-squared test (χ2) and
Fisher F exact test were used. The factors, which could be associated po-
tentially with clinical outcomes, were determined by log regression
analysis. Reclassiﬁcationmethods (C-statistics)were utilized for predic-
tion performance analyses. A calculated difference of P b 0.05 was con-
sidered signiﬁcant.
3. Results
3.1. Study patient population
The characteristics of the patients participated in the study are
depicted in Table 1. At baseline, mean age in box sexes was 58.34
years. The prevalence of II (37.9%) and III (21.4%) NYHA class was deter-
mined. At least 55.5% of the subjects enrolled in the study were hyper-
tensive. Likewise, cardiovascular risk factors, such as dyslipidemia,
type 2 diabetes mellitus and obesity, were reported 66.0%; 37.6%; and
44.3% respectively. Mean left ventricular ejection fraction was
decreased slightly. Subjects who experienced the composite endpoint
presented frequently III–IV NYHA classes, lower estimated glomerular
ﬁltration ratio, as well as higher uric acid, creatinine level, NT-pro-
BNP, hs-CRP, and lipid abnormalities.
The majority of patients with CHF were treated with ACE inhibi-
tors or ARAs, beta-adrenoblockers, I/f blocker ivabradine, mineralo-
corticoid receptor antagonists, and antiplatelet drugs (Table 2).
Adding loop diuretics was done when ﬂuid retention was deter-
mined. Dihydropyridine calcium channel blockers were added to
hypertensive subjects when blood pressure was not controlled by
previous treatment scheme. Metformin and/or sitagliptin wereTable 1
The characteristics of participants.
Entire patient cohort
(n= 388)
Subject
the com
(n= 11
Age, years 58.34 ± 9.60 57.32 ±
Male, n (%) 207 (53.3%) 64 (58.2
I NYHA class, n (%) 77 (19.8%) –
II NYHA class, n (%) 147 (37.9%) 26 (23.6
III NYHA class, n (%) 83 (21.4%) 52 (47.3
IV NYHA class, n (%) 81 (20.9%) 32 (29.1
Hypertension, n (%) 214 (55.5%) 62 (56.4
Dyslipidemia, n (%) 256 (66.0%) 48 (43.6
Type 2 diabetes mellitus, n (%) 146 (37.6%) 42 (38.2
Obesity, n (%) 172 (44.3%) 54 (49.1
Adherence to smoke, n (%) 76 (19.6%) 25 (22.7
BMI, kg/m2 24.1 (95% CI = 21.6–28.7) 23.9 (95
Systolic BP, mm Hg 131 ± 8 130 ± 5
Diastolic BP, mm Hg 78 ± 5 77 ± 4
Heart rate, beats per min 70.52 ± 3.34 74.60 ±
LVEF, % 42.80 ± 5.76 42.20 ±
GFR, 1.73 mL/min/m2 82.3 (95% CI = 68.7–102.6) 81.5 (95
Creatinine, μmol/L 72.3 (95% CI = 58.7–92.6) 73.1 (95
Fasting glucose, mmol/L 5.20 (95% CI = 3.3–9.7) 5.27 (95
HbA1c, % 6.8 (95% CI = 4.1–9.5) 6.9 (95%
Hemoglobin, g/L 135.4 (95% CI = 128.5–140.1) 134.1 (9
Total cholesterol, mmol/L 5.1 (95% CI = 3.9–6.1) 5.3 (95%
Cholesterol HDL, mmol/L 0.91 (95% CI = 0.89–1.12) 0.96 (95
Cholesterol LDL, mmol/L 3.23 (95% CI = 3.11–4.40) 3.71 (95
Uric acid, mmol/L 33.5 (95% CI = 25.3–40.1) 35.7 (95
NT-pro-BNP, pg/mL 1977.2 (95% CI = 984.7–2993.2) 2616.5
hs-CRP, mg/L 7.34 (95% CI = 6.77–7.95) 8.04 (95
Notes: P value was calculated between variables for subjects who experienced the composite e
NYHA— New York Heart Association; GFR— glomerular ﬁltration rate; BMP— brain natriuretic
index, EMPs— endothelial-derived apoptotic microparticles; HbA1c — glycated hemoglobin, Hused in type 2 diabetes patients as a component of contemporary
treatment of CHF. Loop diuretics and aspirin were prescribed fre-
quently in subjects who experienced the composite endpoint. In op-
posite, beta-adrenoblockers, statins and sitagliptin were given
frequently among patients who did not.
3.2. Clinical event determination
Median follow-upwas 2.32 years (IQR=1.8–3.1). During follow-up,
110 cardiovascular events (including 43 fatal cases) were determined.
Thirty ﬁve patients died due to advance of CHF, and eight cases of
death were related with sudden death, fatal myocardial infarction, and
systemic thromboembolism. No other causes of death were deﬁned.
Additionally, 74 subjects were readmitted after discharge from the
hospital due to worsening CHF and 16 subjects were readmitted due
to other cardiovascular reasons.
3.3. Microparticles in CHF patients
As shown in Fig. 1A, total numbers of CD144+/annexin V+
phenotyped endothelial-derivedmicroparticles (EMPs)were not differ-
ent between both patient cohorts (P = 0.22). A double-positive for
CD144 and CD31-staining phenotype of EMPs showed a signiﬁcant in-
crease in patients who experienced the composite endpoints when
compared with those who did not (Fig. 1B). Therefore, Fig. 1C presented
that CD144+/CD31+/annexin V+EMPswere too elevated signiﬁcantly
in subjects who met combined endpoints when compared with patients
who did not (P = 0.001). Mean of circulating apoptotic EMP numbers
(CD31+/annexin V+) in patients who experienced the composite end-
points was higher when compared with mean of EMPs isolated from
peripheral blood from patients who did not (P b 0.001) (Fig. 1D). In con-
trast, activated CD62E+ EMP numbers were not signiﬁcantly different
between the patient's cohorts (P= 0.46) (Fig. 1F).s who experienced
posite endpoint
0)
Subjects who did not experience
the composite endpoint
(n= 278)
P value
6.15 58.73 ± 7.22 0.86
%) 143 (51.4%) 0.88
77 (27.7%) 0.001
%) 121 (43.5%) 0.001
%) 31 (11.2%) 0.001
%) 49 (17.6%) 0.001
%) 152 (54.7%) 0.96
%) 208 (74.8%) 0.024
%) 104 (37.4%) 0.94
%) 118 (42.4%) 0.82
%) 51 (18.3%) 0.77
% CI = 20.7–25.9) 23.3 (95% CI = 21.5–24.8) 0.68
133 ± 5 0.84
78 ± 4 0.92
4.6 69.10 ± 6.2 0.48
3.11 43.20 ± 6.18 0.76
% CI = 71.3–94.7) 83.9 (95% CI = 77.1–102.6) 0.055
% CI = 60.9–80.5) 70.7 (95% CI = 59.1–88.1) 0.048
% CI = 3.5–9.4) 4.98 (95% CI = 3.8–8.1) 0.28
CI = 4.3–9.2) 6.6 (95% CI = 4.6–8.3) 0.36
5% CI = 126.2–136.4) 136.1 (95% CI = 125.1–144.8) 0.06
CI = 4.6–6.0) 5.0 (95% CI = 3.5–5.9) 0.047
% CI = 0.93–1.05) 0.88 (95% CI = 0.84–1.01) 0.044
% CI = 3.50–4.20) 3.53 (95% CI = 3.11–3.97) 0.06
% CI = 25.3–40.1) 31.1 (95% CI = 20.6–36.9) 0.036
(95% CI = 1085.3–3683.5) 1530.6 (95% CI = 644.5–2560.6) 0.042
% CI = 6.81–9.52) 6.96 (95% CI = 5.03–8.13) 0.036
ndpoint and who did not; data were presented asmedian and 95 conﬁdence interval (CI);
peptide; BP— blood pressure; LVEF— left ventricular ejection fraction; BMI— bodymass
DL— high-density lipoprotein; LDL— low-density lipoprotein.
Table 2
Treatment strategy in CHF patients enrolled in the study.
Entire patient cohort
(n= 388)
Subjects who experienced the
composite endpoint (n= 110)
Subjects who did not experience the
composite endpoint (n= 278)
P value
ACE inhibitors or ARAs, n (%) 388 (100%) 110 (100%) 278 (100%) 1.0
Aspirin, n (%) 305 (78.6%) 96 (87.3%) 209 (75.2%) 0.022
Other antiplatelet drugs, n (%) 83 (21.4%) 14 (12.7%) 69 (24.8%) 0.026
Beta-adrenoblockers, n (%) 324 (83.5%) 73 (66.4%) 251 (90.3%) 0.001
Dihydropyridine calcium channel blockers, n (%) 63 (16.2%) 17 (15.5%) 46 (16.5%) 0.88
Ivabradine, n (%) 137 (35.3%) 43 (39.0%) 94 (33.8%) 0.78
Mineralocorticoid receptor antagonists, n (%) 152 (39.2%) 45 (40.9%) 107 (38.5%) 0.66
Loop diuretics, n (%) 311 (80.1%) 110 (100%) 201 (72.3%) 0.043
Statins, n (%) 294 (75.7%) 48 (43.6%) 246 (88.5%) 0.012
Metformin, n (%) 146 (37.6%) 42 (38.2%) 104 (37.4%) 0.86
Sitagliptin, n (%) 48 (12.4%) 9 (8.2%) 40 (14.4%) 0.001
Notes: P value was calculated between variables for subjects who experienced the composite endpoint and who did not; data were presented as number and frequency; ACE— angioten-
sin-converting enzyme; ARAs— angiotensin-2 receptor antagonists.
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EMPs with NYHA class (r = 0.41, P = 0.002), NT-pro-BNP (r = 0.31,
P = 0.001), and LVEF (r = −0.26, P = 0.001) was found. The data
shown that CD144+/CD31+ EMP numbers were positively associated
with NYHA class (r = 0.52, P = 0.001), NT-pro-BNP (r = 0.44, P =
0.003), uric acid (r = 0.40, P = 0.001), hs-CRP (0.33, P = 0.001), and
T2DM (r = 0.32, P = 0.003), and inversely associated with LVEF (r =
−0.32, P = 0.001), and HDL cholesterol (r = −0.221, P = 0.002).
EMP labeled as CD31+/annexin V+ was positively associated with
NYHA class (r = 0.73, P = 0.001), NT-pro-BNP (r = 0.689, P =
0.001), uric acid (r= 0.41, P= 0.001), hs-CRP (0.408, P= 0.006), and
T2DM (r = 0.402, P = 0.003), and inversely associated with LVEF
(r=−0.496, P=0.001), eGFR (r=−0.408, P=0.003), and HDL cho-
lesterol (r=−0.221, P=0.002). Therewas a signiﬁcant association be-
tween CD62E+ EMP number and uric acid (r= 0.312, P= 0.001), hs-
CRP (0.302, P = 0.001), and HDL cholesterol (r =−0.26, P = 0.001).
No signiﬁcant association between the levels of circulating EMPs with
fasting plasma glucose, HbA1c, means systolic and diastolic blood pres-
sure (BP), and medications for both cohorts of the patients was found.
3.4. Predictors of cumulative cardiovascular events
Univariate and multivariate logistic regression were used to assess
whether any biomarker was able to predict better in CHF patients (sub-
jects who experienced the composite endpoint versus who did not).
Univariate logistic regression analysis shown that themain factors inde-
pendently related with cumulative endpoints were creatinine, fasting
glucose, HbA1c, total cholesterol, serum uric acid, various types of
EPMs, NT-pro-BNP, hs-CRP, NYHA class, decreased LVEF (less 45%),
and T2DM (Table 3). In multivariate model NYHA class, LVEF less 45%,
NT-pro-BNP, hs-CRP, CD144+/CD31+/annexin V+ EMPs, and
CD31+/annexin V+ EMPs remained statistically signiﬁcant for cumu-
lative endpoint.
We used reclassiﬁcationmethods aimed to deﬁnewhether the addi-
tion of EMCs labeled as CD144+/CD31+/annexin V+ and CD31+/
annexin V+ to the standard ABC model constructed with NYHA class,
decreased LVEF (less 45%), NT-pro-BNP, and hs-CRP to improve the dis-
criminate value of the model. The analysis of obtained result showed
that adding CD144+/CD31+/annexin V+ EMCs and CD31+/annexin
V+ EMCs to the standard ABC model may improve the relative IDI for
cumulative endpoint by 11.4% and 10.5% respectively. For category-
free NRI, 5% of events (P = 0.003) and 6% of non-events (P = 0.001)
were correctly reclassiﬁed by the addition of CD144+/CD31+/annexin
V+ EMCs to the ABC model. When we added CD31+/annexin V+
EMCs to the ABC model, 3% and 4% of events (P = 0.001 for all cases)
for category-free NRI and 6% and 7% of non-events (P = 0.001 for all
cases) were correctly reclassiﬁed. Thus, apoptotic phenotype ofcirculating EMPs may relate to 3-year combined clinical outcomes in
CHF patients.
4. Discussion
This study demonstrates that EMPs obtained from peripheral blood
in CHF patientsmay contribute in clinical outcomes. However, EMPpat-
terns in patients who experienced cumulative events and subjects who
did not were different. Predominantly apoptotic proﬁle of circulating
EMPs was presented through CD144+/CD31+/annexin V+ EMPs
and CD31+/annexin V+ EMPs. The numbers of apoptotic EMPs in pa-
tients who met cumulative clinical outcomes were signiﬁcantly higher
when compared with those who did not. No sufﬁcient difference be-
tween both patient cohorts regarding numbers of EMPs appeared to
be in peripheral blood in resulting activation of the endothelial cells.
Therefore, there was lack of signiﬁcant difference in low speciﬁc EMPs
labeled as CD144+/annexin V+microparticles in patients who experi-
enced cumulative clinical outcomes and those who did not. Overall,
these ﬁndings mirror that apoptotic EMP pattern appears to be nega-
tively prognostically potent for CHF patient population. Therefore, it is
shown that the EMP proﬁlemay be considered a useful tool for determi-
nation of the CHF patients with poor prognosis. Indeed, adding of
CD144+/CD31+/annexin V+ EMCs and CD31+/annexin V+ EMCs
to the standard ABC model that was constructed with contemporary
predictive biomarkers, including NYHA class, decreased LVEF (less
45%), NT-pro-BNP, and hs-CRP, allows to improve the discriminate
value of the standard model.
Because EMPs are considered a mediator for inﬂammatory re-
sponses that may contribute in vascular wall injury [26], the results of
the study support the hypothesis about the pivotal role of endothelial
dysfunction in worsening of CHF. Recent investigations show that vari-
ous stimuli, such as shear stress, inﬂammation, and vascular damage
may potentiate to realize EMPs by two leading ways: via secretion
from activated endothelial cells and via induction of endothelial cell ap-
optosis [27,28]. As shown circulating EMPs derived from activated en-
dothelial cells play a pivotal role in tissue repair, transcellular
exchange of information, and neoangiogenesis [29]. In opposite,
apoptotic-derived EMPs contribute in vascular damage through stimu-
lation of tissue factor-dependent procoagulant activity, free-radical
hyper-production and inﬂammation, leukocyte adhesion, and altered
vasomotion [30–33]. Biological effects of EMPs realize via the induction
of the speciﬁc cellular properties that leads to activation of membrane-
associated receptors on the surface of wide spectrum of target cells, in-
cluding endothelial cells, and mononuclears [34]. We suggested that
predominantly elevated apoptotic EMPs create opportunity for
reprogramming and phenotype modiﬁcation of endothelial cells that
lead to worsening of endothelial dysfunction and as a result in poor
Fig. 1.Comparison of theproﬁle of circulating endothelial-derivedmicroparticles in patientswhoexperienced the composite endpoint (Cohort 1) andwhodid not (Cohort 2). Values for all
ﬁgures are mean and SD (standard deviation) and were compared using Student's paired t-test. A. CD144+/annexin V+ EMP numbers isolated from peripheral blood from both cohort
patients. B. Circulating CD144+/CD31+ EMPs in both cohort patients. C. CD144+/CD31+/annexin V+ EMP numbers isolated from circulation from both cohort patients. D. CD31+/
annexin V+ EMP numbers isolated from peripheral blood from both cohort patients. F. CD62E+ EMP numbers isolated from peripheral blood from both cohort patients.
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ciﬁc for CHF only andmay determine in other cardiovascular andmeta-
bolic diseases [35,36], the exact innate mechanisms affecting
predominantly elevation of apoptotic-derived EMPs in CHF are still
not understood and required detailed investigations. In fact, the patients
with a higher EMP level had a higher risk of future cardiovascular events
including major adverse cardiovascular events, recurrent hospitaliza-
tions and death [34–36]. Moreover, the interrelation between peripher-
al endothelial dysfunction and cardiovascular events at high-risk
patients may contribute in realizing the apoptotic phenotype of EMPs
[37,38]. The results of our investigations showed that numbers of
apoptotic-derived EMPs better predict clinical outcomes in CHF patientsthan activated endothelial cell-derivedmicroparticle pattern. In support
of this issuewe have recently reported that increased apoptotic EMPs to
progenitor mononuclear cell ratio was a better predictor when com-
pared with isolated decreased proangiogenic progenitor mononuclears,
which are suitable for patients with CHF [39]. Thus, apoptotic pheno-
type of EMPs is essential for cardiac failure subjects with short-term
poor outcomes. These data are very promising, and they require a new
investigation with higher statistical power and increased sample size
to overcome the internal limitations of the study.
In conclusion, we suggest that apoptotic phenotype of EMPs labeled
as CD144+/CD31+/annexin V+ and CD31+/annexin V+ may be
considered as a useful tool for determination of CHF patients with
Table 3
Univariate and multivariate regression analyses.
Variances Univariate analysis Multivariate analysis
OR 95% CI Р value OR 95% CI Р value
NYHA class 1.15 1.03–1.29 0.006 1.06 1.01–1.09 0.001
T2DM (present vs. absent) 1.05 1.01–1.09 0.006 1.03 0.89–1.07 0.001
LVEF less 45% (present vs. absent) 1.56 1.23–1.72 0.002 1.17 1.04–1.25 0.003
Creatinine per 30 μmol/L 1.06 1.01–1.11 0.001 1.02 0.87–1.06 0.001
Fasting glucose per 3 mmol/L 1.04 0.96–1.09 0.002
HbA1c per 1% 1.05 1.01–1.07 0.002
Total cholesterol per 1 mmol/L 1.08 1.01–1.09 0.001
Uric acid per 10 mmol/L 1.08 1.03–1.09 0.001 1.03 0.92–1.08 0.001
NT-pro-BNP per 400 pg/mL 1.97 1.25–3.06 0.001 1.37 1.08–2.10 0.001
hs-CRP per 1 mg/L 1.32 1.22–1.57 0.001 1.12 1.03–1.25 0.001
CD144+/annexin V+ EMPs per 0.3/mL 1.02 1.00–1.04 0.001 0.96 0.89–1.10 0.001
CD144+/CD31+ EMPs per 0.5/mL 1.04 1.02–1.06 0.001 1.02 0.94–1.05 0.001
CD144+/CD31+/annexin V+ EMPs per 0.6/mL 1.34 1.18–1.62 0.006 1.19 1.12–1.33 0.001
CD31+/annexin V+ EMPs per 0.2/mL 1.18 1.10–1.27 0.001 1.07 1.02–1.13 0.001
CD62E+ EMPs per 0.15/mL 1.03 1.00–1.08 0.001 0.99 0.94–1.05 0.001
Notes: CI— conﬁdence interval; OR— odds ratio; HbA1c— glycated hemoglobin; BNP — brain natriuretic peptide; EMPs — endothelial-derived apoptotic microparticles.
23A.E. Berezin et al. / BBA Clinical 3 (2015) 18–24poor prognosis. Finally, identiﬁcation of the pattern of circulating EMPs
may help to determine patients at high risk and reclassify it for possible
biomarker-guided therapy of CHF.
5. Study limitations
This study has some limitations. It is necessary to note that a large
pool of nanoparticles might be produced after blood sampling due to
destruction of platelets and blood cells. Therefore, preparation of iso-
lates of microparticles in the samples is the most sophisticated step
for further examination. Venous citrated blood drawn from the ﬁstula-
free armwas performed obligatorily.Webelieve that these risks are sys-
temic, and to minimize them, we refused to freeze the blood samples
before measurement of microparticles. Therefore, there were several
technical-related difﬁculties in the measurement of EMPs. In fact,
therewas a lack of standardprotocol for isolating anddetecting circulat-
ing EMPs obtained from the plasma. According to the opinion of the
majority of experts, centrifugation has become the main factor mediat-
ed reliability of the EMP determination in samples and contributed in
biological variability of EMP count. Although HD-FACS methodology is
widely used, theoretically overlap between two or more ﬂuorochromes
might reﬂect some obstacles for further interpretation of obtained
results. Another limitation of the present study is that a speciﬁc role of
EMPs is also possible and has not been characterized in depth in CHF
patients especially with various comorbidities. However, the authors
suppose that these restrictions might have no signiﬁcant impact on
the study data interpretation. Additionally, retrospective, relative
small sample size may limit the signiﬁcance of the present study.
However, this was not a randomized and controlled study. The authors
believe that a greater cohort of patients with more incidences detected
is desirable to improve the credibility of the study.
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